JPH07504668A - 抗体の免疫原性の選択的改変法 - Google Patents

抗体の免疫原性の選択的改変法

Info

Publication number
JPH07504668A
JPH07504668A JP5516130A JP51613093A JPH07504668A JP H07504668 A JPH07504668 A JP H07504668A JP 5516130 A JP5516130 A JP 5516130A JP 51613093 A JP51613093 A JP 51613093A JP H07504668 A JPH07504668 A JP H07504668A
Authority
JP
Japan
Prior art keywords
antibody
antibodies
response
reduced
hama
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5516130A
Other languages
English (en)
Japanese (ja)
Inventor
サイクス、トーマス、アール．
レディッシュ、マーク
ボーム、リチャード　ピィ．
ノージャイム、アントイン　エィ．
Original Assignee
バイオミラ、インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオミラ、インコーポレーテッド filed Critical バイオミラ、インコーポレーテッド
Publication of JPH07504668A publication Critical patent/JPH07504668A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP5516130A 1992-03-18 1993-03-18 抗体の免疫原性の選択的改変法 Pending JPH07504668A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85360592A 1992-03-18 1992-03-18
US853,605 1992-03-18
PCT/CA1993/000110 WO1993018792A1 (fr) 1992-03-18 1993-03-18 Alteration selective de l'immunogenicite des anticorps

Publications (1)

Publication Number Publication Date
JPH07504668A true JPH07504668A (ja) 1995-05-25

Family

ID=25316485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5516130A Pending JPH07504668A (ja) 1992-03-18 1993-03-18 抗体の免疫原性の選択的改変法

Country Status (7)

Country Link
EP (1) EP0631507A1 (fr)
JP (1) JPH07504668A (fr)
AU (1) AU3881593A (fr)
CA (1) CA2131621A1 (fr)
FI (1) FI944314A0 (fr)
NO (1) NO943388L (fr)
WO (1) WO1993018792A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
JP2002504154A (ja) * 1997-06-17 2002-02-05 アルタレックス コーポレイション 治療用組成物および治療方法
US8796425B2 (en) 2009-12-23 2014-08-05 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816249A (en) * 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies

Also Published As

Publication number Publication date
FI944314A (fi) 1994-09-16
NO943388D0 (no) 1994-09-12
EP0631507A1 (fr) 1995-01-04
AU3881593A (en) 1993-10-21
WO1993018792A1 (fr) 1993-09-30
NO943388L (no) 1994-11-18
CA2131621A1 (fr) 1993-09-30
FI944314A0 (fi) 1994-09-16

Similar Documents

Publication Publication Date Title
ES2141467T5 (es) Anticuerpos anti-cd30 que evitan la escision proteolitica y liberacion del antigeno cd30 fijado a la membrana.
US7183388B2 (en) Anti-MUC-1 single chain antibodies for tumor targeting
US7608263B2 (en) RG1 antibodies and uses thereof
ES2219699T3 (es) Anticuerpo monoclonal br110 y usos del mismo.
KR920700692A (ko) 사람의 종양과 연합한 신규 항원에 대한 신규의 일클론 항체
JP6233933B2 (ja) 葉酸リセプターα及びβを認識する抗体
JP2005538682A (ja) カルボキシックアンヒドラーゼｉｘ（ｃａｉｘ）腫瘍抗原に対する抗体
KR910700077A (ko) 인체 종양과 관련된 신규 항원에 대한 신규한 모노클로날 항체
CN108047331A (zh) 用于癌症诊断的针对密蛋白18.2的抗体
NZ222509A (en) Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
JP2005516965A (ja) 抗ｍｕｃ１８抗体を使用する方法
US5034223A (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
JP2005514409A (ja) Ｍｕｃ１８抗原に対する抗体の使用
ES2823648T3 (es) Métodos y composiciones para tratar y prevenir enfermedades asociadas con la integrina AVB8
WO2006032127A1 (fr) Mediation de cytotoxicite de cellules mettant en evidence l'expression superficielle de mcsp
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
EP0288520B1 (fr) Usage et composition permettant d'ameliorer le ciblage d'anticorps, de fragments d'anticorps, et de leur conjuges
PT81418B (pt) Processo para a preparacao de anticorpos monoclonais e de antigenicos, para carcinomas do pulmao de celulas nao-pequenas humanas
JP2004536578A (ja) 腫瘍ターゲティング用の抗−ｍｕｃ−１単鎖抗体
WO2003093315A2 (fr) Fragments d'anticorps specifiques pour l'antigene carcinoembryonaire (ace) humain
CZ174198A3 (cs) Molekuly protilátek a způsob diagnózy
JPH06169791A (ja) ヒト腫瘍に関する新しい抗原に対する新しいモノクローナル 抗体
JPH07504668A (ja) 抗体の免疫原性の選択的改変法
AU2004289821B2 (en) Adenocarcinoma specific antibody SAM-6, and uses thereof
JP3513173B2 (ja) モノクローナル抗−ガングリオシド抗体、その製造およびそれを含有する腫瘍治療剤